Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma
Authors:
- 15 May 2013
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (12) , 2606-2612
Abstract
(2013). Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. Leukemia & Lymphoma: Vol. 54, No. 12, pp. 2606-2612.Keywords
This publication has 33 references indexed in Scilit:
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaBlood, 2011
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironmentBlood, 2011
- Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2011
- DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphomaBlood, 2010
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphomaBlood, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome predictionBlood, 2006
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993